Why Shares In SkyePharma PLC Crashed Over 15% Today

SkyePharma PLC (LON: SKP) is heavily in the red today. Here’s why.

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Today’s update from SkyePharma (LSE: SKP) was, on the face of it, rather encouraging. After all, the oral and inhalation drug development company announced that its full year results for 2014 are expected to be in-line with board’s previous guidance. However, shares in the company are down by over 15% at the time of writing, which makes them the biggest faller in the FTSE All-Share today. Here’s why that’s the case.

Disappointing News

The sale of products that use technology licensed by SkyePharma to GlaxoSmithKline were below market expectations in the third quarter. While disappointing, SkyePharma still expects the royalties it receives to reach the cap of £9 million per annum, but it now anticipates that this will take place a year later than had previously been expected. The impact of this on the company’s share price, though, has  been substantial, with investor sentiment sharply declining due to concerns regarding whether more disappointing sales numbers will be reported over the short to medium term.

In addition, there will be an exceptional cost included in SkyePharma’s 2014 results. That’s because the company will now reimburse some of the restructuring costs related to its manufacturing business and premises in Lyon, France, which are currently leased to Aenova France. Although unlikely to be a hugely significant cost, this may also have hurt investor sentiment in SkyePharma.

Looking Ahead

Despite this, SkyePharma appears to be performing relatively well and, as mentioned, is expected to meet full-year expectations that will see it deliver a pre-tax profit for the first time since 2010. And, looking ahead, the company expects to ramp up investment in SKP-2075 and novel oral drug delivery platform technologies, as well as increasing net investment in research and development in a number of newly identified areas.

Furthermore, its performance in 2014 has benefitted from a £1.6 million milestone payment following the launch of Flutiform in Spain in the fourth quarter, with the company also receiving a slice of increased sales of Exparel. Both of these developments are encouraging and highlight that SkyePharma is well-placed to benefit from further sales growth in both of these areas.

In addition, SkyePharma continues to have a relatively robust balance sheet that seems to position it well to build on its anticipated return to profitability in 2014. And, with shares in the company trading on a price to earnings (P/E) ratio of just 10, they seem to offer good value for money at the present time. So, while investor sentiment may have taken a major knock today, SkyePharma could prove to be a sound long term buy.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Peter Stephens owns shares of GlaxoSmithKline. The Motley Fool UK has recommended shares in GlaxoSmithKline. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Could the JD Sports Fashion share price double in the next five years?

The JD Sports Fashion share price has nearly halved in the past five years. Our writer thinks a proven business…

Read more »

Bus waiting in front of the London Stock Exchange on a sunny day.
Investing Articles

If interest rate cuts are coming, I think these UK growth stocks could soar!

Falling interest could be great news for UK growth stocks, especially those that have been under the cosh recently. Paul…

Read more »

Investing Articles

Are these the best stocks to buy on the FTSE right now?

With the UK stock market on the way to hitting new highs, this Fool is considering which are the best…

Read more »

Petrochemical engineer working at night with digital tablet inside oil and gas refinery plant
Investing Articles

Can the Centrica dividend keep on growing?

Christopher Ruane considers some positive factors that might see continued growth in the Centrica dividend -- as well as some…

Read more »

Smiling family of four enjoying breakfast at sunrise while camping
Investing Articles

How I’d turn my £12,000 of savings into passive income of £1,275 a month

This Fool is considering a strategy that he believes can help him achieve a stable passive income stream with a…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

2 top FTSE 250 investment trusts trading at attractive discounts!

This pair of discounted FTSE 250 trusts appear to be on sale right now. Here's why I'd scoop up their…

Read more »

Smiling young man sitting in cafe and checking messages, with his laptop in front of him.
Investing Articles

3 things that could push the Lloyds share price to 60p and beyond

The Lloyds share price has broken through 50p. Next step 60p? And then what? Here are some thoughts on what…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

£1,000 in Rolls-Royce shares a year ago would be worth this much now

Rolls-Royce shares have posted one of the best stock market gains of the past 12 months. But what might the…

Read more »